Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Curaleaf Holdings Inc T.CURA

Alternate Symbol(s):  CURLF

Curaleaf Holdings, Inc. is an international provider of consumer cannabis products. The Company and its brands, including Curaleaf, Select, Grassroots, JAMS, Find and Zero Proof provide selection and accessibility across the medical and adult use markets. It operates in approximately 17 states and owns and operates 147 dispensaries and 21 cultivation sites with a focus on states, including... see more

TSX:CURA - Post Discussion

View:
Post by Saxman on Sep 15, 2024 9:05am

Germany

Medical Cannabis - Germany

  • Germany
  • Germany is expected to see a projected revenue of US$499.80m in the Medical Cannabis market market by 2024.
  • The revenue is forecasted to exhibit a CAGR of 3.54% between 2024 and 2029, leading to a market volume of US$594.80m by 2029.
  • When compared globally, the United States is anticipated to generate the highest revenue in 2024, amounting to US$14,530.00m.
  • In terms of per person revenues in 2024, US$1.51k are generated based on total population figures.
  • Germany's Medical Cannabis market is rapidly expanding, with increasing patient access and growing acceptance of its therapeutic benefits.
 

 

Be the first to comment on this post
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities